Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press14610.17650/1994-4098-2011-0-1-70-75GYNECOLOGY. DIAGNOSISГИНЕКОЛОГИЯ. ДИАГНОСТИКАThe pathomorphological characteristics of clear-cell adenocarcinomas of the ovary and its mixed tumors with a clear-cell componentПатоморфологическая характеристика светлоклеточных аденокарцином яичников и смешанных злокачественных опухолей яичников со светлоклеточным компонентомAkhmedovaM.. DАхмедоваМ. Д.
Russian Federation
ShabanovM. A.ШабановМ. А.
Russian Federation
BarinovV. V.БариновВ. В.
Russian Federation
ZhordaniaK. I.ЖорданиаК. И.
Russian Federation
BokinaL. I.БокинаЛ. И.
Russian Federation
MustafinaE. A.МустафинаЕ. А.
Russian Federation
afl_nlo154@mail.ruN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowРОНЦ им. Н.Н. Блохина РАМН, Москва250220111707525072014250720142011https://ojrs.abvpress.ru/ojrs/article/view/146

Objective: to study the pathomorphological signs of pure and mixed clear-cell ovarian tumors with a clear-cell component.Subjects and methods. The clinical and morphological characteristics and the course of the disease were analyzed in 96 patients aged 21 to 75 years with clear-cell ovarian carcinoma. All the patients were divided into 2 groups: 1) 71 patients with pure clear-cell ovarian adenocarcinomas (COA) and 2) 25 patients with mixed malignant ovarian epithelial tumors (MMOET) with an obligatory clear-cell component. All pure forms of ovarian clear-cell malignancies were represented by adenocarcinoma in our study. This histologic type of the tumor was also prevalent among mixed ovarian neoplasms.Results. Clear, optically transparent cells and shoe nail-type (nail) ones were most common in COA. MMOETs showed moderate dif- ferentiation and malignancy and moderate atypia of a cell. Pure clear-cell neoplasms generally displayed 3 to 6 mitoses in 10 fields of vision whereas MMOET exhibited as many as 3 mitoses in 10 fields of vision.

clear-cell ovarian adenocarcinomasmixed malignant ovarian epithelial tumors with a clear-cell componentclinical and morphological signsсветлоклеточные аденокарциномы яичниковсмешанные злокачественные опухоли яичников со светлоклеточным компонентомклинические и морфологические признаки1. Жорданиа К.И. Злокачественные новообразования яичников. Энциклопедия клинической онкологии. М., 2004.Жорданиа К.И. Злокачественные новообразования яичников. Энциклопедия клинической онкологии. М., 2004.2. Короленкова Л.И. Светлоклеточные (мезонефроидные) опухоли женских половых органов. Дис. ... канд. мед. наук. М., 1983.Короленкова Л.И. Светлоклеточные (мезонефроидные) опухоли женских половых органов. Дис. ... канд. мед. наук. М., 1983.3. Fine G., Clarke H., Horn R. Mesonephroma of the ovary. Cancer 1973;31: 398–410.Fine G., Clarke H., Horn R. Mesonephroma of the ovary. Cancer 1973;31: 398–410.4. Kennedy A.W., Biscotti C.V., Hart W.R., Tuason L.J. Histologic correlates of progression-free interval and survival in ovarian clear cell adenocarcinoma. Gynecol Oncol 1993;50(3):334–8.Kennedy A.W., Biscotti C.V., Hart W.R., Tuason L.J. Histologic correlates of progression-free interval and survival in ovarian clear cell adenocarcinoma. Gynecol Oncol 1993;50(3):334–8.5. Pettersson F. Annual report of the results of treatment in gynecological cancer. Stockholm, International Federation of Gynecology and Obstetrics, 1991.Pettersson F. Annual report of the results of treatment in gynecological cancer. Stockholm, International Federation of Gynecology and Obstetrics, 1991.6. Behbakht K., Randall TюCю, Benjamin I. et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998;70(20):255–8.Behbakht K., Randall TюCю, Benjamin I. et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998;70(20):255–8.7. Nishino K., Aoki Y., Amikura T. et al. Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. Gynecol Oncol 2005;97:893–7.Nishino K., Aoki Y., Amikura T. et al. Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. Gynecol Oncol 2005;97:893–7.8. Skirnisdottir I., Seidal T., Karlsson M.G. et al. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I–II. Int J Oncol 2005;26:177–83.Skirnisdottir I., Seidal T., Karlsson M.G. et al. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I–II. Int J Oncol 2005;26:177–83.9. Scully R.E. Ovarian tumors. J Pathol 1977;87:686.Scully R.E. Ovarian tumors. J Pathol 1977;87:686.10. Young R.H., Scully R.E. Oxyphilic clear cell carcinoma of the ovary. A report of nine cases. Am J Surg Pathol 1987;11(9):661–7.Young R.H., Scully R.E. Oxyphilic clear cell carcinoma of the ovary. A report of nine cases. Am J Surg Pathol 1987;11(9):661–7.